These BRAF inhibitors, administered in combination with MEK inhibitors, resulted in rapid therapeutic responses, with significant improvements in both progression-free and overall survival in large fractions of metastatic MM patients [2,15]. The gene discussed is MAP2K7; the disease is Miyoshi myopathy.